Turn on more accessible mode
Turn off more accessible mode
Sign Up to Receive PSA Updates
It looks like your browser does not have JavaScript enabled. Please turn on JavaScript and try again.
Sign Up to Receive PSA Updates
It looks like your browser does not have JavaScript enabled. Please turn on JavaScript and try again.
Toggle navigation
menu
It looks like your browser does not have JavaScript enabled. Please turn on JavaScript and try again.
Sign Up to Receive PSA Updates
Toggle navigation
menu
Sign Up to Receive PSA Updates
It looks like your browser does not have JavaScript enabled. Please turn on JavaScript and try again.
Advisories & Events
PATIENT SAFETY journal
News
Training & Events
Related Organization Links
Advisory Archive
Pennsylvania Patient Safety Advisory
Advisory Archive
November 2, 2009, Vol. 6, Suppl. Alert
Share
Download
Masthead
2009supalert
From the Database
Confusion Regarding Concentration of Tamiflu® Oral Suspension
A shortage of commercially available Tamiflu® (oseltamivir phosphate) oral suspension is contributing to dosing errors in healthcare facilities. The Pennsylvania Patient Safety Authority has received two reports related to the concentration of Tamiflu. In each case, it was thought that the commercially available 12 mg/mL product and not a pharmacy-compounded 15 mg/mL suspension would be dispensed.
